

Osteopontin

Human FW= 32,000

Mouse FW = 31,500

Rat FW = 44,000

Human plasma:

- men with hormone refractory prostate carcinoma: median 198.5 ng/mL (range 15-2363 ng/mL) (1)
- healthy volunteers: 315.1 +/- 117.4 ng/mL (2)
- hemodialysis patients: 837.3 +/- 443.2 ng/mL (2)
- women with metastatic breast carcinoma: median 142 ug/L (range 38-1312 ug/L) (3)
- women on follow-up after cancer treatment: median 60 ug/mL (range 15-117 ug/L) (3)
- female healthy controls: median 47 ug/L (range 22-122 ug/L) (3)
- healthy women: median 31 ug/L (range 14-64 ug/L) (4)

Human serum:

- prostate cancer patients: 653 +/- 39 ng/mL (5)
- colon cancer patients: 449 +/- 22 ng/mL (5)
- breast cancer patients: 814 +/- 53 ng/mL (5)
- lung cancer patients: 724 +/- 33 ng/mL (5)
- normal sera: 435 +/- 30 ng/mL (5)

Human urine:

- Normal controls: 21.4 +/- 6.2 mg/g Cr (6)
- IgA nephropathy patients: 11.6 +/- 9.6 mg/g Cr (6)

Mouse serum:

- Tg over-expressing OPN: 782 +/- 107 ng/mL (7)
- Non-Tg mice: 182 +/- 44 ng/mL (7)

Rat cells:

- Antisense aortic vascular smooth muscle cells after stimulation: 257 +/- 102 ng/mL (8)
- Sense aortic vascular smooth muscle cells: 473 +/- 104 ng/mL (8)
- Empty vector vascular smooth muscle cells: 434 +/- 66 ng/mL (8)

- (1): Hotte SJ, et al., (2002) Cancer; 95(3):506-12--→ELISA
- (2): Nitta K, et al., (2001) Nephron; 89(4):455-8--→ ELISA
- (3): Singhal H, et al., (1997) Clin Cancer Res; 3(4):605-11.
- (4): Bautista DS, et al., (1996) Clin Biochem; 29(3):231-9.
- (5): Fedarko NS, et al., (2001) Clin Cancer Res ; 7(12):4060-6--→ELISA
- (6): Gang X, et al., (2001) Am J Kidney Dis; 27(2):374-9.
- (7): Isoda K, et al., (2002) Circ Res; 91(1):77-82.
- (8): Weintraub AS, et al., (1996) Am J Pathol; 149(1):259-72.